secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0000950170-23-027257
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara CTO Charlene Banard departs; signs consulting deal through Sept 2023
--------------------------------------------------------------------------

- Charlene Banard, EVP and Chief Technical Officer, left Atara on June 9, 2023.
- She entered a consulting agreement with Atara from June 9 through September 30, 2023.
- Consulting fee: $2,000 monthly for up to specified hours, plus $220/hr for excess hours.
- Her outstanding equity awards will continue to vest during the consulting term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023027257/0000950170-23-027257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023027257/atra-20230609.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer